Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories’New Drug Application (NDA) for Efavirenz Tablets

By Pharmaceutical Processing | December 22, 2009

Mylan Inc. has announced that its subsidiary Matrix Laboratories Limited has receivedtentative approval from the FDA under thePresident’s Emergency Plan for AIDS Relief (PEPFAR) for its New DrugApplication (NDA) for Efavirenz Tablets, 50 mg, 100 mg and 200 mg. Theseinnovative pediatric dosages in tablet form were developed by Matrix for usein treating pediatric HIV/AIDS. Mylan President Heather Bresch commented: “This New Drug Applicationrepresents another successful innovation by Matrix in the fight againstHIV/AIDS. Our HIV/AIDS antiretroviral (ARV) franchise continues to grow and tobring more affordable, high quality medications to patients in the developingworld. We are extremely pleased to be able to add these new dosages to thebasket of treatment options currently available to the medical community, andto expand our portfolio of products for treating pediatric HIV/AIDS.”Efavirenz is a non-nucleoside reverse transcriptase inhibitor (nNRTI) thathas been found to be effective in many combination regimens for the treatmentof HIV infection, both in treatment-naive and in treatment-experiencedindividuals. The FDA’s tentative approval under PEPFAR means that Matrix’s productmeets all of the agency’s manufacturing quality, safety and efficacystandards. Although existing patents or exclusivity prevent its marketing inthe U.S., the product will be eligible for purchase outside the U.S. in manydeveloping countries.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE